As of the latest Form 4 filed Oct 22, 2025.
What AngioDynamics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 32 most recent filings for ANGO.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-10-22 | 2025-10-21 | Weiss Lawrence T SVP, Chief Legal Officer | PPurchase | +10.0K | $11.81 | $118K | No | Form 4 ↗ |
| 2025-10-14 | 2025-10-13 | Trowbridge Stephen A EVP and CFO | PPurchase | +890.00 | $11.16 | $9.93K | No | Form 4 ↗ |
| 2025-10-09 | 2025-10-09 | Clemmer James C President and CEO | PPurchase | +10.0K | $11.15 | $112K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-21 | Trowbridge Stephen A EVP and CFO | FTax | −667.00 | $8.99 | $6.00K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-21 | Nighan Warren JR SVP Quality and Regulatory | FTax | −277.00 | $8.99 | $2.49K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-21 | Campbell Chad Thomas SVP/GM, Vascular Access | FTax | −395.00 | $8.99 | $3.55K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-20 | Trowbridge Stephen A EVP and CFO | FTax | −717.00 | $8.69 | $6.23K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-20 | Piccinini Laura SVP International | FTax | −616.00 | $8.69 | $5.35K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-20 | Nighan Warren JR SVP Quality and Regulatory | FTax | −251.00 | $8.69 | $2.18K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-20 | Clemmer James C President and CEO | FTax | −3.67K | $8.99 | $33.0K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-20 | Clemmer James C, President and CEO | FTax | −2.98K | $8.69 | $25.9K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-20 | Campbell Chad Thomas SVP/GM, Vascular Access | FTax | −359.00 | $8.69 | $3.12K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-19 | Trowbridge Stephen A EVP and CFO | FTax | −2.58K | $8.69 | $22.5K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-19 | Piccinini Laura SVP International | FTax | −1.98K | $8.69 | $17.2K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-19 | Nighan Warren JR SVP Quality and Regulatory | FTax | −735.00 | $8.69 | $6.39K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-19 | Clemmer James C President and CEO | FTax | −8.31K | $8.69 | $72.2K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-19 | Clemmer James C, President and CEO | FTax | −344.00 | $8.69 | $2.99K | No | Form 4 ↗ |
| 2025-07-22 | 2025-07-19 | Campbell Chad Thomas SVP/GM, Vascular Access | FTax | −1.02K | $8.69 | $8.91K | No | Form 4 ↗ |
| 2025-07-21 | 2025-07-17 | Piccinini Laura SVP International | FTax | −3.07K | $8.74 | $26.9K | No | Form 4 ↗ |
| 2025-07-18 | 2025-07-16 | Piccinini Laura SVP International | AAward | +32.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-18 | 2025-07-16 | Nighan Warren JR SVP Quality and Regulatory | AAward | +29.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-18 | 2025-07-16 | Clemmer James C President and CEO | AAward | +206K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-18 | 2025-07-16 | Weiss Lawrence T SVP, Chief Legal Officer | AAward | +30.9K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-18 | 2025-07-16 | Trowbridge Stephen A EVP and CFO | AAward | +87.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-18 | 2025-07-16 | Campbell Chad Thomas SVP/GM, Vascular Access | AAward | +26.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-18 | 2025-07-16 | DONNELLY HOWARD W Director | AAward | +17.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-18 | 2025-07-16 | Burgess Lorinda Director | AAward | +17.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-18 | 2025-07-16 | Auen Eileen O'Shea Director | AAward | +17.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-18 | 2025-07-16 | Tarnoff Michael E Director | AAward | +17.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-18 | 2025-07-16 | REED JAN STERN Director | AAward | +17.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-18 | 2025-07-16 | Licitra Karen A Director | AAward | +17.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-18 | 2025-07-16 | JOHNSON WESLEY Director | AAward | +17.7K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ANGO’s full analysis or the market-wide insider trading feed. The tabs above jump to ANGO’s other SEC data.
Source: SEC Form 4 filings for ANGO, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.